Search Results - "ARBIZU, T"

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study by Comi, G, Prof, Pulizzi, A, MD, Rovaris, M, MD, Abramsky, O, Prof, Arbizu, T, MD, Boiko, A, Prof, Gold, R, Prof, Havrdova, E, Prof, Komoly, S, Prof, Selmaj, KW, Prof, Sharrack, B, MD, Filippi, M, MD

“…Summary Background A 24-week phase II trial has shown that 0·3 mg of laquinimod given daily to patients with relapsing-remitting multiple sclerosis was well…”
Get full text

Volatile Compounds, Odour and Flavour Attributes of Lamb Meat from the Navarra Breed as Affected by Ageing by Insausti, Kizkitza, Murillo-Arbizu, María T, Urrutia, Olaia, Mendizabal, José A, Beriain, María J, Colle, Michael J, Bass, Phillip D, Arana, Ana

“…This study aimed to assess the influence of ageing on the volatile compounds, as well as odour and flavour attributes of lamb meat from the Navarra breed…”
Get full text

Physicochemical and Sensory Assessments in Spain and United States of PGI-Certified Ternera de Navarra vs. Certified Angus Beef by Beriain, María José, Murillo-Arbizu, María T., Insausti, Kizkitza, Ibañez, Francisco C., Cord, Christine Leick, Carr, Tom R.

“…The physicochemical and sensory differences between the PGI-Certified Ternera de Navarra (CTNA) (Spanish origin) and Certified Angus Beef (CAB) (US origin)…”
Get full text

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study by Comi, G., Abramsky, O, Arbizu, T, Boyko, A, Gold, R, Havrdová, E, Komoly, S, Selmaj, K, Sharrack, B, Filippi, M

“…Background: Laquinimod, an oral novel immunomodulator, was shown to reduce MRI-measured disease activity in relapsing—remitting MS (RRMS) patients. Objectives:…”
Get full text

Association of HLA-DRB115 allele and CSF oligoclonal bands in a Spanish multiple sclerosis cohort by Romero-Pinel, L., Martínez-Yélamos, S., Bau, L., Matas, E., Gubieras, L., María Pujal, J., Morandeira, F., Bas, J., Arbizu, T.

“…Background and objective:  The HLA‐DRB1*15 allele is consistently associated with multiple sclerosis (MS) susceptibility in most studied populations. This…”
Get full text

Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (The Novo Study) by Fernández, O., Fernández, V., Arbizu, T., Izquierdo, G., Bosca, I., Arroyo, R., García Merino, J. A., de Ramón, E.

“…Multiple sclerosis (MS) is a disease supposedly of autoimmune origin, with reactivity directed against myelin antigens. From the neuropathological point of…”
Get full text

Effect of glatiramer acetate (Copaxone ®) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: A longitudinal study by Blanco, Y., Moral, E.A., Costa, M., Gómez-Choco, M., Torres-Peraza, J.F., Alonso-Magdalena, L., Alberch, J., Jaraquemada, D., Arbizu, T., Graus, F., Saiz, A.

“…We assessed the effect of glatiramer acetate (GA) on the immunophenotypic and cytokine profile and the BDNF production by peripheral blood mononuclear cells,…”
Get full text

HLA-DRB1: genetic susceptibility and disability progression in a Spanish multiple sclerosis population by Romero-Pinel, L., Pujal, J. M., Martínez-Yélamos, S., Gubieras, L., Matas, E., Bau, L., Torrabadella, M., Azqueta, C., Arbizu, T.

“…Background and objective:  The association of HLA‐DRB1*15 with susceptibility to multiple sclerosis (MS) has been consistently reported although its effect on…”
Get full text

Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS by SAIZ, A, BLANCO, Y, CARRERAS, E, BERENGUER, J, ROVIRA, M, PUJOL, T, MARIN, P, ARBIZU, T, GRAUS, F

“…The authors report the outcome of 14 patients with severe multiple sclerosis treated with autologous hematopoietic stem cell transplantation (AHSCT) after a…”
Get full text

Anticipation of age at onset in familial multiple sclerosis by Romero-Pinel, L., Martínez-Yélamos, S., Gubieras, L., Matas, E., Bau, L., Kremenchutzky, M., Arbizu, T.

“…Background and objective:  Anticipation of age at onset in the younger generations is a widely known characteristic of many diseases with genetic inheritance…”
Get full text

Consensus Statement on medication use in multiple sclerosis by the Spanish Society of Neurology's study group for demyelinating diseases by García-Merino, A, Fernández, O, Montalbán, X, de Andrés, C, Oreja-Guevara, C, Rodríguez-Antigüedad, A, Arbizu, T

“…Treatments for multiple sclerosis therapy are rapidly evolving. It is believed that new drugs will be approved in the near future, thereby changing current…”
Get more information

Multiple sclerosis and cognitive decline: is ApoE-4 a surrogate marker? by Carmona, O., Masuet, C., Santiago, O., Alía, P., Moral, E., Alonso-Magdalena, L., Casado, V., Arbizu, T.

“…Carmona O, Masuet C, Santiago O, Alía P, Moral E, Alonso‐Magdalena L, Casado V, Arbizu T. Multiple sclerosis and cognitive decline: is ApoE‐4 a surrogate…”
Get full text

Spanish Neurology Society consensus document on the use of drugs in multiple sclerosis: escalating therapy by García Merino, A, Fernández, O, Montalbán, X, de Andrés, C, Arbizu, T

“…Treatment of multiple sclerosis has advanced considerably in the last few years, at the same time as its complexity has increased. The purpose of this…”
Get full text

Idiopathic acute transverse myelitis: a clinical study and prognostic markers in 45 cases by Bruna, J, Martínez-Yélamos, S, Martínez-Yélamos, A, Rubio, F, Arbizu, T

“…Objective The Transverse Myelitis Consortium Working Group has proposed new diagnostic criteria for idiopathic acute transverse myelitis (ATM). We reviewed…”
Get full text

MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS by SAIZ, A, CARRERAS, E, BERENGUER, J, YAGÜE, J, MARTINEZ, C, MARIN, P, ROVIRA, M, PUJOL, T, ARBIZU, T, GRAUS, F

“…To analyze the MRI and CSF oligoclonal bands (OB) changes in patients with MS who underwent an autologous hematopoietic stem cell transplantation (AHSCT)…”
Get full text

PND19 Cost Of The Relapse Of Multiple Sclerosis In Spain by Gubieras, L, Casado, V, Romero-Pinel, L, Matas, E, Bau, L, Martínez-Yélamos, S, López, M, Escartín, A, Arbizu, T

Get full text

PND23 Cost of the Informal Care of Multiple Sclerosis in Spain by Gubieras, L, Casado, V, Romero-Pinel, L, Matas, E, Bau, L, Martínez-Yélamos, S, Arbizu, T

Get full text

Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease by Graus, F, Dalmau, J, Valldeoriola, F, Ferrer, I, Reñé, R, Marin, C, Vecht, Ch.J, Arbizu, T, Targa, C, Moll, J.W.B

“…We studied an autoantibody (called anti-Tr), found in the serum and CSF of five patients with paraneoplastic cerebellar degeneration (PCD) and Hodgkin's…”
Get full text

14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis by MARTINEZ-YELAMOS, A, SAIZ, A, SANCHEZ-VALLE, R, CASADO, V, RAMON, J. M, GRAUS, F, ARBIZU, T

“…Axonal damage probably occurs early in the evolution of MS. Five of 38 (13%) patients had a positive assay for the neuronal 14-3-3 protein in the CSF obtained…”
Get full text

Anticipation of age at onset in multiple sclerosis: methodologic pitfalls by Alonso-Magdalena, L., Romero-Pinel, L., Moral, E., Carmona, O., Gubieras, L., Ramón, J. M., Martínez-Yélamos, S., Arbizu, T.

“…Alonso‐Magdalena L, Romero‐Pinel L, Moral E, Carmona O, Gubieras L, Ramón JM, Martínez‐Yélamos S, Arbizu T. Anticipation of age at onset in multiple sclerosis:…”
Get full text